Matthew McClure has been appointed executive vice president and chief medical officer of South San Francisco-based Aligos Therapeutics. He was most recently the chief medical officer of Second Genome. McClure’s experience also includes time at InterMune, which was acquired by Roche in 2014. Preclinical-stage Aligos is developing treatments for liver diseases and viral infections.
From Our Editors · Special Report
Learn what's fueling San Diego's biotech investment and partnership opportunities
From Our Editors · Special Report
Top biotech and investment players offer their best plans and current progress in stemming and ultimately defeating the worldwide pandemic
From Our Editors · Podcast
Learn what's fueling Boston's biotech and digital health investment and partnership opportunities
